20 articles
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
Clinical trial explores whether resetting gut microbiome through fecal transplants can slow Parkinson's progression and reduce symptoms.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
A Phase II trial tests whether blocking herpes virus activity can protect against Alzheimer's disease in early cognitive decline.
Phase 1b trial tests escalating doses of experimental Alzheimer's treatment BMS-984923 for safety and tolerability in older adults.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
Applied Cognition tests a wearable device that tracks glymphatic function overnight, comparing it to MRI, EEG, and blood biomarkers.
24-week trial tested fucoxanthin-rich microalgae supplement on memory, attention, and executive function in 66 healthy seniors.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
The EPICURO trial tests MERIVAยฎ turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
Nine-year study investigated whether solanezumab could slow memory decline in older adults with brain amyloid plaques.
A Phase 4 real-world study comparing extended-release methylphenidate formulations for ADHD was terminated before yielding conclusions.
A completed pilot trial tests whether 2g/day of a novel carnosine formulation can restore neuromuscular function and quality of life in MS patients.
Eight-week mindfulness program tested for women experiencing severe menopause symptoms after preventive ovary removal surgery.
A pilot trial tests whether group and phone-based CBT can sharpen cognition and cut chronic stress in African Americans at risk for Alzheimer's.
A completed RCT tests whether 6 months of moderate aerobic exercise protects memory and brain structure in older adults at genetic risk for Alzheimer's.
French researchers followed 1,028 people with mild cognitive complaints to understand how dementia develops over time.
Small trial tested whether fish oil and alpha lipoic acid could slow Alzheimer's by reducing oxidative stress markers in blood.
